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SUMMARY – A severe complication of the administration of bisphosphonate-containing me-
dications is known as bisphosphonate-associated osteonecrosis of the jaws (BONJ). A case series of 
three patients affected by BONJ is presented. These patients currently represent the only described 
cases of BONJ in Bulgaria. Exposed necrotic bone of the mandible was observed in two patients 
and the maxilla was affected in the third case. Two of the patients had been treated with zoledronate 
for metastatic prostate cancer and one patient for metastatic endometrioid cancer. All three patients 
underwent surgical treatment. One of the patients received conservative surgical debridement, i.e. 
removal of necrotic bone only, and primary wound closure. Conservative surgical debridement and 
application of local medications without wound closure were used in the other two patients. All 
three patients received systemic antibiotic treatment. No evidence of disease progression was obser-
ved during the follow-up period of 3 to 12 months. The surgical approach utilized in the present 
study is discussed in the light of the etiopathogenesis, prevention and treatment of BONJ.
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Introduction
Avascular osteonecrosis of the jaws is a serious 
complication associated with the use of bisphospho-
nate medications1. It is known as bisphosphonate-
associated osteonecrosis of the jaws (BONJ) and has 
been reported widely in the literature in the past 6 
years. BONJ has been defined as necrosis, associated 
with or unrelated to dental procedures, which persists 
for more than 6 to 8 weeks2 and is refractory to conser-
vative treatment3. It should occur in patients who have 
not received any radiotherapy in the affected area, but 
have been treated for a disease characterized by bone 
resorption with bisphosphonates intravenously for 
at least one year, or orally for a much longer period. 
The incidence of BONJ, as reported in the literature, 
ranges between 1.3%2 and 10%4. At present, there is 
disagreement on the treatment of BONJ due to only 
few evidence-based studies5-9. Therefore, efforts are 
focused on the opportunities for its prevention10.
The aim is to report on the first series of three pa-
tients with BONJ in Bulgaria, diagnosed and treated 
surgically at Department of Maxillofacial Surgery, 
Plovdiv, Bulgaria.
Case Reports
A 73-year-old male patient presented with a chief 
complaint of pain in the frontal aspect of the upper 
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jaw where the frontal teeth had fallen out sponta-
neously. The patient was diagnosed with metastatic 
prostate carcinoma 40 months before his presentation. 
He had received 4 mg of zoledronate (ZometaR) in in-
travenous infusions on a monthly basis during this pe-
riod. No radiotherapy in the head and neck area had 
been performed. Intermittent pain had been present 
in the upper jaw for 21 months after the beginning of 
bisphosphonate administration. Exposed bone with 
necrotic appearance, dark brown in color and with 
porous surface was found on the labial side of the 
maxillary anterior alveolar ridge. The lesion dimen-
sions were 4 to 6 cm in diameter and it was surround-
ed by hyperemic gingiva, which was extremely painful 
to palpation. The second left and right maxillary inci-
sors were mobile and painful, with purulent discharge 
from the periodontal pockets (Fig. 1). Diagnostic 
investigations consisted of a panoramic radiograph 
and computer tomography (CT) without contrast for 
the exact measurement of the lesion. The radiograph 
demonstrated bone resorption and CT investigation 
confirmed the presence of osteonecrotic areas in the 
anterior maxilla, described as multiple lesions of low 
density and oval, round and strip-like shapes (Fig. 2). 
The second left and right maxillary incisors were not 
salvageable and had to be extracted; the wounds were 
sutured. Debridement of the necrotic area was carried 
out under local anesthesia. There was no possibility of 
primary closure with flap from adjacent tissues. The 
remaining exposed bone above the sutured extraction 
wounds was treated with antibiotic ointment (gentam-
icin cream 0.1%, Actavis, Bulgaria) daily for a week. 
After the pain and signs of suppuration disappeare 
d, local treatment was changed to the application of 
5.0% Solcoseryl (Solco Ltd., Australia) twice per day. 
Systemic antibiotic treatment included intravenous 
administration of benzylpenicillin sodium (Penicil-
lin GR, Balkanpharma, Bulgaria) four times daily in 
doses of 2 000 000 IU for 10 days, followed by phe-
noxymethyl penicillin (OspenR, Sandoz GmbH, Aus-
tria) in coated tablets of 1500 IU three times daily for 
15 days. The pathology investigation of the necrotic 
bone confirmed bisphosphonate-associated osteone-
crosis of the maxilla with findings of necrotic bone 
and degenerated stratified squamous epithelium with-
out presence of actinomyces colonies (Fig. 3). Dur-
ing the follow-up, the patient no longer complained 
of pain. The local signs of inflammation disappeared. 
The exposed bone was continually treated locally as 
noted. The patient is still under observation.
A 54-year-old female patient presented with a 
painful swelling under the right and left lower jaw. 
The swelling was recurrent and first appeared after the 
placement of complete dentures six months before her 
Fig. 1. A patient with bisphosphonate-associated osteonecro-
sis of the anterior maxilla.
Fig. 2. Computed tomography scan of the maxilla in the 
patient with bisphosphonate-associated osteonecrosis of the 
jaws. 
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first examination at Department of Maxillofacial Sur-
gery. The patient had been diagnosed with metastatic 
endometrioid carcinoma 45 months before her refer-
ral, and was surgically treated for cancer. She received 
a total of 42 courses of zoledronate (ZometaR) in in-
travenous infusions of 4 mg monthly. No additional 
chemotherapy was used. The complete dentures were 
fabricated 36 months after the start of bisphosphonate 
treatment. The clinical intraoral examination revealed 
hyperemia of the oral mucosa of the buccal vestibule 
of the anterior mandible on the right and exposed 
bone on the lingual side of the posterior mandible on 
the left. The bone surfaces in the anterior labial region 
on the right and the posterior lingual region on the 
left were exposed by a mucoperiostal flap under lo-
cal anesthesia. The bone was presented with porous 
structure and white chalk color. The macroscopically 
altered bone was removed by curettage and subsequent 
grinding, and examined pathologically. The pathology 
result reported bone tissue with necrosis, but without 
actinomyces colonies. Wound healing was unevent-
ful. The patient underwent a 14-day course of intra-
venous administration of benzylpenicillin sodium 
(Penicillin GR, Balkanpharma, Bulgaria) four times 
daily in doses of 2 000 000 IU, followed by a 30-day 
course of oral phenoxymethyl penicillin (OspenR, 
Sandoz GmbH, Austria) in coated tablets 1500 IU 
three times daily. No pain was present at the follow-
up examination 1 month after the surgery. The patient 
is being followed up and an assessment of the need for 
renewing bisphosphonate treatment is to be made by 
her oncologist.
A 78-year-old male patient presented with severe 
pain and swelling in the left half of the lower jaw, 
which had started several days before the examina-
tion. The lower first left molar had been extracted more 
than three months before, but the extraction wound 
had not healed yet. The patient was surgically treated 
for metastatic prostate cancer. The patient had received 
18 courses of zoledronate (ZometaR), 4 mg in intrave-
nous infusions monthly before presenting to the De-
partment of Maxillofacial Surgery. Medical history 
also showed diabetes type 2 and anemia. On clinical 
examination, a non-healed, open extraction wound 
was visible. The bone had yellowish color and putrid 
smell. The surrounding mucosa demonstrated signs of 
inflammation and was markedly painful on palpation. 
CT examination of the head and neck revealed an ir-
regular, hypodense bone defect in the horizontal ramus 
of the mandible, which disrupted the continuity of the 
lateral cortical plate. Surgical debridement with curet-
tage without primary flap closure was performed un-
der local anesthesia. Pathology reported a diffuse and 
pronounced inflammatory process with a large number 
of leukocytes and signs of transition to chronic state. 
No signs of malignancy and no presence of actinomy-
ces colonies were found. The exposed bony surface was 
treated daily with antibiotic ointment packing (0.1% 
gentamicin cream, Actavis, Bulgaria). At the follow-up 
examination 1 month after surgery, the pain had sub-
sided, and pus formation had ceased. Treatment was 
continued by alternating local application of antibiotic 
ointment (0.1% gentamicin cream, Actavis, Bulgaria) 
and 5.0% Solcoseryl (Solco Ltd., Australia). The patient 
also received cefotaxime (Tchaikapharma, Bulgaria), 3.0 
g per day intravenously for 7 days. At discharge, the 
patient had no pain or signs of inflammation. Conser-
vative local treatment of the bisphosphonate-associated 
necrosis of the jaw continued, with close follow-up of 
the patient’s oral status.
Patient data are summarized in Table 1.
Discussion
Bisphosphonates are synthetic analogues of inor-
ganic pyrophosphates with powerful inhibitory effect 
on osteoclastic activity. They get incorporated in skel-
etal bone. Bisphosphonates bind to Ca2++ in regions of 
Fig. 3. Microscopic view of necrotic bone in bisphosphonate-
associated osteonecrosis of the jaws.
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high bone turnover, and remain integrated in the bone 
for more than 10 years11; for example, the half-life of 
alendronate is assumed to be 12 years. Once incorpo-
rated, they start a cascade of biochemical processes re-
sulting in the loss of the ability of osteoclasts to resorb 
bone, or even in apoptosis. They are used in the treat-
ment of diseases characterized by a high level of bone 
resorption, such as multiple myeloma, osteolytic bone 
metastases, Paget’s bone disease12, fibrous dysplasia13, 
McCune-Albright syndrome14, tumor-induced hy-
percalcemia, and osteoporosis. More than 2.5 million 
patients worldwide are assumed to be treated with bis-
phosphonates15.
BONJ could be the result of bone metabolism sup-
pression found after bisphosphonate treatment and due 
to the accumulation of physiologic micro-injuries to 
jaw bones compromising their biomechanical proper-
ties10. Trauma and infection increase the need for bone 
remodeling, which exceeds the capacity of the hypody-
namic bone and leads to localized bone necrosis. Sook-
Bin Woo et al.10 assume that bisphosphonate-associated 
osteonecrosis develops only in jaw bones because they 
are insufficiently protected as compared to other bones 
in the body. It is essential that they are shielded against 
possible intraoral trauma only by the thin mucosa and 
periosteum. The presence of teeth in the jaws is a pre-
condition for easy invasion of microorganisms and de-
velopment of bony infections, by way of dental caries 
complications and periodontal disease. An interesting 
fact is that oral bone appears to be particularly resistant 
to infection even if the mucosal layer covering the bone 
is disrupted. Probably human beta-defensin antimicro-
bical peptides 1, 2 and 3 in jaw bone could be the me-
diator of innate immunity16. 
All of the reported patients received bisphosphonates 
for their bone metastases from carcinomas (prostate 
and endometrioid). Literature data show that bispho-
sphonate treatment is most frequently used in patients 
with multiple myeloma because of bone involvement 
and lung cancer with metastasis in the bones4,10.
All patients in the present study were treated with 
intravenous administration of amino-bisphosphonate, 
zoledronate (ZometaR). According to Dannemann et 
al.17, all cases of osteonecrosis of the jaws described 
prior to 2006 were associated with the administration 
of bisphosphonates containing an amino group. Pub-
lished reports disagree on the question which amino-
bisphosphonates induce BONJ more frequently, but 
scientific evidence tends to support the prevailing 
notion that the use of zoledronate carries the great-
est risk4,18. Our cases confirm the data reported by 
Dannemann et al.17, suggesting that the most com-
monly reported cases are associated with intravenous 
bisphosphonate treatment and only a small number of 
cases of jaw osteonecrosis after continued oral use of 
alendronate (FosamaxR) to treat osteoporosis. Sook-
Bin Woo et al.10 report that 94% of BONJ patients re-
ceived pamidronate or zoledronate intravenously, and 
6% of them took oral bisphosphonates as treatment for 
osteoporosis or Paget’s disease.
Table 1. Summary of cases with bisphosphonate-associated osteonecrosis of the jaws
Age and sex 73/male 54/female 78/male
Diagnosis Prostate cancer Endometrioid cancer Prostate cancer
Oral precipitant Spontaneous Pressure spots from total denture Dental extraction
Affected jaw Maxilla Mandible Mandible
Type of bisphosphonate Zoledronate (ZometaR) Zoledronate (ZometaR) Zoledronate (ZometaR)
Route of administration IV IV IV
Duration of 
bisphosphonate treatment 40 months 42 months 18 months
Treatment Local debridement & conservative treatment
Local debridement & 
primary closure
Local debridement & 
conservative treatment
Outcome No progression after 12 months
No progression after 3 
months No information
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The presence of actinomyces colonies was not con-
firmed in the present series, although they were found 
to be the most common microbiological finding17. 
In all three cases, the pathology investigation ruled 
out diagnosis corresponding to the principal condition 
treated with bisphosphonates. It consistently found 
necrotic bone surrounded by bacteria but not invading 
it, thus also excluding the possibility of osteomyeli-
tis. Three main histologic patterns were identified in 
BONJ patients: 1) areas with active acute inflamma-
tion, characterized by predominance of soft tissues, 
inflammatory infiltrate, acellular necrotic debris, 
thin-walled and dilated blood vessels, and intensely 
basophilic bone spicules with scalloped borders show-
ing prominent bone resorption; 2) areas characterized 
by predominance of bony structures showing wide 
acellular necrotic sequestra and large, scalloped hav-
ersian canals containing inflammatory cells; and 3) 
non-necrotic areas contained larger amounts of bone, 
showing increased trabecular thickness, inter-osteon-
ic bone deposition and smaller and fewer haversian 
canals. Also, lamellar bone from treated patients was 
composed of bigger osteones containing larger osteo-
cytes. Two different types of newly-formed woven 
bone, mainly showing centrifugal spatial orientation, 
were easily detectable in these areas. Osteoclast-like 
cells detected in inflammatory areas from treated pa-
tients were small and contained few nuclei, but they 
were rare to absent in non-necrotic bone from the 
same patients19.
The patients in this study received intravenous bis-
phosphonates for 18 to 42 months. Bamias et al.4 be-
lieved that there was a strict correlation between the 
duration of bisphosphonate treatment and the mani-
festation of jaw necrosis. They found that the median 
time of exposure to bisphosphonates for patients with 
BONJ was 39.3 (11 to 86) months, and for patients 
without BONJ 19 (4 to 84.7) months. The authors re-
port that the cumulative risk of BONJ development 
increased above 1% after 12 months of treatment and 
up to 11% at 4 years. They also found the risk to de-
pend on the type of bisphosphonate used; for zole-
dronate it was 1% within the first year of treatment 
and up to 21% at 3 years, while for pamidronate it was 
0% for the first 2 years, increasing to 7% after 4 years. 
Corso et al.18 have defined the following time periods 
for the development of BONJ in relation to the type 
of bisphosphonate: treatment with pamidronate leads 
to necrosis not earlier than 23 months after initiation 
of therapy; this period is not shorter than 28 months 
with zoledronate treatment; after combined use of 
pamidronate and zoledronate, necrosis could not be 
observed earlier than 43 months. Badros et al.20 found 
that the risk of developing BONJ increased by 57% 
per each year after diagnosis of multiple myeloma was 
made and bisphosphonate treatment initiated.
In two of the patients presented, BONJ occurred 
after dental extractions, while in the third one it was 
due to pressure-induced injury by a new complete 
denture. Literature review showed that cases of BONJ 
preceded by dental procedures prevailed over cases of 
the so called spontaneous BONJ4,20, with 33% to 86% 
of all cases developing after different dental proce-
dures14.
The patients presented in this report were aged 73, 
54 and 78 years. It has been reported that the risk of 
developing BONJ increases by 9% for each decade of 
life20.
Different authors have not reached agreement on 
whether bisphosphonate treatment should be stopped 
after osteonecrosis of the jaws has been diagnosed. 
Marx et al.21 suggest that continuation of bisphos-
phonate treatment in oncology patients should be 
discussed with the oncologists and the benefit to risk 
ratio assessed in view of the long half-life (more than 
10 years) of bisphosphonates. Dunstan et al.22 believe 
that bisphosphonate therapy should be discontinued. 
In our opinion, discontinuation of bisphosphonate 
treatment is not justified in patients with metastatic 
cancer. The AAOMS is paper marked the treatment 
goals: control of pain, control of secondary infection, 
and prevention of extension of lesion and development 
of new areas of necrosis3. 
One of our patients was treated by lesion debri-
dement and flap coverage with local tissues. Most 
authors23,24 recommend that this approach should be 
avoided because of the risk of necrotic involvement of 
new bone areas. It is, however, our preferred method 
in case of relatively small necrotic area and presence 
of sufficient adjacent soft tissues without inflamma-
tory infiltration. The other two patients were treated 
with periodic debridement of necrotic areas leaving 
exposed bone and antibiotic application, for reduction 
of symptoms. This is a treatment protocol advocated 
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by Graziani et al.25, who, however, did not exclude the 
possibility for sequestrectomy and resection in some 
cases. The AAOMS position is that surgical treat-
ment should be delayed if possible, and the extrac-
tion of symptomatic teeth within exposed, necrotic 
bone should be considered since it is unlikely that 
the extraction will exacerbate the established necrotic 
process3. In the literature, the opinion prevails that 
aggressive surgical treatment is counter-productive, 
results in worsening of the condition, and therefore 
should be avoided15,23,24,26. We recommend early re-
moval of all bone surfaces with macroscopic necrotic 
appearance with or without flap coverage. Nastro et 
al.27 emphasize that antibiotics could not penetrate 
necrotic tissues and hence should be only used to in-
fluence cellulitis in neighboring tissues. Our results 
confirmed this opinion as evidenced by disappearance 
of pain and signs of inflammation at follow-up exami-
nations 1 month after the surgery and after systemic 
antibiotic treatment. 
Conclusion
The proven benefits of bisphosphonates have re-
sulted in their widespread use in certain patient groups 
in Bulgaria too. Consequently, this has led to the de-
velopment of specific complications such as BONJ. 
The present case series comprises only three patients, 
but the number of cases diagnosed with BONJ in 
Bulgaria will increase with increasing awareness and 
more common and prolonged use of bisphosphonates. 
Despite the relatively short follow-up periods, the re-
sults of the present study made us believe that early 
detection and minimally invasive surgical treatment 
of BONJ in conjunction with antibiotic medication 
(cephalosporin-type for 7 to 10 days intravenous or 
penicillin-type for at least 20 days) ensure the best 
therapeutic results. 
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Sažetak
OSTEONEKROZA ČELJUSTI UDRUŽENA S BISFOSFONATIMA – TRI PRIKAZA SLUČAJA
I PREGLED LITERATURE
P. Pechalova, A. Bakardjiev, Z. Zaprianov, B. Vladimirov, E. Poriazova, A. Zheleva, G. Hadjigeorgiev, 
V. Goranova-Marinova i S. Goranov
Teška komplikacija terapije lijekovima koji sadrže bisfosfonate poznata je kao osteonekroza čeljusti udružena s bisfos-
fonatima. Prikazuju se tri bolesnika s osteonekrozom čeljusti udruženom s bisfosfonatima i to su zasad jedini opisani slu-
čajevi ove bolesti u Bugarskoj. Dvoje bolesnika imalo je izloženu nekrotičnu kost mandibule, dok je u trećeg bila zahvaćena 
maksila. Bolesnici su bili liječeni zoledronatom, u dva slučaja zbog metastatskog raka prostate, a u trećem slučaju zbog 
metastatskog endometrioidnog karcinoma, i svi su bili podvrgnuti kirurškom zahvatu. Kod jednog bolesnika primijenjen 
je konzervativni kirurški debrideman, tj. uklanjanje samo nekrotičnog tkiva, uz primarno zatvaranje rane. U drugih dvoje 
bolesnika primijenjen je konzervativni kirurški debrideman i lokalna medikamentna terapija bez zatvaranja rane. Svi bole-
snici primili su sistemsku antibiotsku terapiju. Tijekom razdoblja praćenja od 3 do 12 mjeseci nisu zabilježeni nikakvi znaci 
progresije bolesti. Raspravlja se o kirurškom pristupu primijenjenom u ovoj studiji u odnosu na etiopatogenezu, prevenciju 
i liječenje osteonekroze čeljusti udružene s bisfosfonatima.
Ključne riječi: Osteonekroza – kirurgija; Bolesti čeljusti, kemijski uzrokovane; Bisfosfonati – štetni učinci; Kirurški postupci, 
operacijski 
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